Atea Pharmaceuticals (AVIR) Assets Average (2020 - 2026)

Atea Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $291.1 million for Q1 2026.

• In Q1 2026, Assets Average fell 35.63% year-over-year to $291.1 million; the TTM figure through Mar 2026 stood at $291.1 million (down 35.63% YoY), while the FY2025 annual figure was $389.9 million, down 26.4% from the prior year.
• Assets Average for Q1 2026 stood at $291.1 million, down from $329.1 million in the prior quarter.
• The five-year high for Assets Average was $745.0 million in Q1 2022, with the low at $291.1 million in Q1 2026.
• The 5-year median for Assets Average is $574.0 million (2024), against an average of $544.8 million.
• The sharpest annual moves came in 2023 and 2026: Assets Average retreated 10.44% in 2023, then plunged 35.63% in 2026.
• Atea Pharmaceuticals' Assets Average stood at $676.6 million in 2022, then dropped by 11.1% to $601.5 million in 2023, then slipped by 20.57% to $477.8 million in 2024, then plunged by 31.13% to $329.1 million in 2025, then declined by 11.53% to $291.1 million in 2026.
• Business Quant data shows AVIR's Assets Average at $291.1 million in Q1 2026, $329.1 million in Q4 2025, and $367.3 million in Q3 2025.